The Office of Cancer Genomics (OCG), along with the Office of HIV and AIDS Malignancies (OHAM), initiated the HIV+ Tumor Molecular Characterization Project (HTMCP) to gain insight into the genetic events driving HIV-associated cancers and to determine why certain cancers, but not others, have higher incidences in HIV-positive patients. The molecular characterization data from patients identified through HTMCP will be available to the research community worldwide in a publicly available, yet patient privacy-protected database.
Acquired immunodeficiency syndrome (AIDS) is a complex and devastating disease caused by infection with human immunodeficiency virus (HIV). The advent of highly active anti-retroviral therapy (HAART) has considerably slowed disease progression from HIV to full-blown AIDS, thereby increasing the number of people living with HIV. Despite this success in survivorship, certain types of cancers are becoming more prevalent in the expanding pool of HIV-infected individuals. This poses a challenge to global health, since at the end of 2017 approximately 36.9 million people were living with HIV worldwide (25.7 million in Sub-Saharan Africa and over 1.1 million in the US, according to the UNAIDS, World Health Organization, and HIV.gov). While co-infecting viruses and, possibly, immunodeficiency may play a role in the pathogenesis of HIV-associated cancers, our understanding of its etiology is inadequate. Understanding the molecular causes of these tumors may translate into improved therapies for a growing population of patients doubly afflicted with HIV and cancer.
HTMCP is an ongoing project; diffuse large B-cell lymphoma (DLBCL) and lung cancer projects are currently in Phase II of the timeline. Cervical cancer project is in Phase IV of the timeline.
Visit the CGCI Overview page to learn more about the general timeline of CGCI projects.